A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
This is a multicenter, open-label, phase II study of YL201 in China to evaluate the efficacy, safety, and PK characteristics of YL201 on mCRPC.
Trial Details
- NCT ID
- NCT06241846
- Phase
- PHASE2
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Status
- RECRUITING
- Cancer Type
- Prostate Cancer
- Interventions
- Locations (sample)
- Hefei, Anhui, China|31.86389,117.28083
- Hefei, Anhui, China|31.86389,117.28083
- Beijing, Beijing Municipality, China|39.9075,116.39723
- Beijing, Beijing Municipality, China|39.9075,116.39723
- Hunan, Changsha, China|32.92741,120.18021
Key Eligibility Criteria
- Subjects who understand relevant information of the study prior to initiation of the study and voluntarily sign and date on the ICF.
- Age ≥ 18 years.
- Patients should meet the following conditions to be enrolled:
- Histologically or cytologically confirmed prostate cancer. Note: The primary histological classification indicated by biopsy should be adenocarcinoma;
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Prostate Cancer Trials on Trialify →